SBSuzanne Botts

Suzanne Botts

*This is an algorithmically generated author record based on publicly available information.

Suzanne Botts has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Daniela Ennulat

    GlaxoSmithKline, Chair, Clinical Pathology Working Group, King of Prussia, PA, USA

    1 shared publication
  • Mark Graham

    AstraZeneca, Member, Clinical Pathology Working Group, Loughborough, Leicestershire, UK

    1 shared publication
  • Michael Mohutsky

    Lilly Research Laboratories, Eli Lilly and Company, Member, Risk Assessment Working Group, Indianapolis, IN, USA

    1 shared publication
  • Robert R. Maronpot

    Maronpot Consulting LLC, Chair, Anatomic and Ultrastructural Pathology Working Group, Raleigh, NC, USA

    1 shared publication
  • Sabine Francke-Carroll

    CFSAN US FDA, Chair, Risk Assessment Working Group, College Park, MD, USA

    1 shared publication

Latest Publications

  • Open Access

    Introduction to Hepatic Drug Metabolizing Enzyme Induction in Drug Safety Evaluation Studies

    by Suzanne Botts, Daniela Ennulat, Sabine Francke-Carroll, Mark Graham, Robert R. Maronpot, Michael Mohutsky

    The following three articles represent the output of a combined effort initiated by the Scientific Regulatory Policy Committee of the Society of Toxicologic Pathology to provide a unified review of current scientific practices and relevant literature and provide suggestions regarding the recognition, interpretation, and risk assessment of hepatic drug metabolizing enzyme (DME) induction studies. The core objective was to provide a review that the scientific community including pathologists, regulatory scientists, toxicologists, investigative scientists, and others would find valuable for managing, designing, and interpreting toxicity studies supporting regulatory filings. Three working groups composed of scientists from industry, academia, and regulatory agencies were convened to review the available literature on important aspects of the interpretation and risk assessment of hepatic microsomal DME enzyme induction in three publications. The three reviews are as follows: “Effects of Hepatic Drug Metabolizing Enzyme Induction on Clinical Pathology Parameters in Animals and Man,” Toxicol Pathol “Hepatic Drug Metabolizing Enzyme Induction: Microscopic and Ultrastructural Appearance,” Toxicol Pathol “Hepatic Drug Metabolizing Enzyme Induction and Implications for Preclinical and Clinical Risk Assessment,” Toxicol Pathol The purpose of this introduction is not to summarize the articles but rather to frame the series and to provide a common mechanistic introduction.